// App-Quantinova.ai

: Availability of drug susceptibility testing to new/re-purposed anti-tuberculosis drugs: a TBnet study

Researchers

Presenter

  • Lorenzo Guglielmetti

Principal Investigators

  • Claude Leu

  • Gunar Günther

  • Graham Bothamley

  • Christoph Lange

  • Frank Van Leth

Medical Centers

  • VU University, Amsterdam, Netherlands

  • Sorbonne Université, INSERM, U1135, Centre d’Immunologie et des Maladies Infectieuses, Cimi-Paris, équipe 13; 2) APHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France

  • Research Center Borstel, Borstel, Germany; 2) German Center for Infection Research (DZIF), Germany; 3) University of Lübeck, Lübeck, Germany, Borstel, Germany

  • Thoracic Medicine, Homerton University Hospital, London, United Kingdom,

  • Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern; 2) Department of Medicine, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia, Bern, Switzerland

  • Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland

Locations

  • United Kingdom

  • Switzerland

  • Germany

  • France

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Tuberculosis

Biomarkers

  • N/A

Drug/Treatment

  • Bedaquiline

  • Lamprene

  • rifampicin

  • Deltyba

  • Linezolid

Outcome

  • N/A

Study Design

  • Cross-Sectional

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved